|
|
|
NEW YORK (AP) - Shares of Momenta Pharmaceuticals Inc. rose Thursday after an analyst upgraded the stock, saying Momenta will soon receive marketing approval for its version of the anti-clotting drug Lovenox. Momenta expects...
ORLANDO (MedPage Today) -- The oral anti-coagulant dabigatran did not appear to markedly increase major bleeding rates among post-MI patients who were already being treated with aspirin and clopidogrel (Plavix), researchers...
Marathon Oil, Time Warner, GameStop, Sears, Whole Foods are among big market movers Thursday NYSE: Marathon Oil Corp., down $1.37 at $33.33 The company will cut capital expenditures in 2010, with a larger percentage of funds...
Nov 18 (Reuters) - : * Canaccord adams starts Cytokinetics Inc with buy rating; price target of $7 * Canaccord adams starts Momenta Pharmaceuticals with buy rating; price target of $17 * Canaccord adams starts XOMA Ltd with buy...
CAMBRIDGE, Mass., Nov. 12, 2009 (GLOBE NEWSWIRE) -- Momenta Pharmaceuticals, Inc. (Nasdaq:MNTA), a biotechnology company specializing in the characterization and engineering of complex drugs, today announced that Richard P....
Teva Pharmaceutical Industries is seeking to add infringement of three additional patents on its multiple sclerosis drug Copaxone to its claims against Momenta Pharmaceuticals and Sandoz. The amended complaint seeks to include...
6:36AM On The Wires : Lattice Semiconductor (LSCC) announces that it will collaborate with Beyond Semiconductor in the development of compiler tools for Lattice's soft processors. The collaboration will include updates and...
Teva claims that the MS drug is a "highly-complicated product to develop and manufacture." ) wants to add three more patents to its Copaxone patent-infringement lawsuit filed against Momenta Pharmaceuticals, Inc./Sandoz Inc....
November 06, 2009 | about: Q3 2009 Earnings Call Transcript Executives Beverly Holley – Director, IR Craig Wheeler – President and CEO Rick Shea – VP and CFO Analysts Bret Holley – Oppenheimer & Co. Eric Schmidt – Cowen and...
CAMBRIDGE, Mass., Nov. 5, 2009 (GLOBE NEWSWIRE) -- Momenta Pharmaceuticals, Inc. (Nasdaq:MNTA), a biotechnology company specializing in the characterization and engineering of complex drugs, today reported its financial results...
